{"id":20480,"date":"2018-07-26T13:03:15","date_gmt":"2018-07-26T11:03:15","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=20480"},"modified":"2026-10-09T16:32:52","modified_gmt":"2026-10-09T14:32:52","slug":"leading-companies-make-switch-to-veeva-opendata-to-deliver-accurate-data-faster-to-field-teams","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/leading-companies-make-switch-to-veeva-opendata-to-deliver-accurate-data-faster-to-field-teams\/","title":{"rendered":"Leading Companies Make Switch to Veeva OpenData to Deliver Accurate Data Faster to Field Teams"},"content":{"rendered":"

Organizations from emerging biopharma to the largest pharmaceutical companies are improving field productivity and driving better customer engagement<\/em><\/p>\n

BARCELONA, Spain \u2014 26 July 2018 \u2014 <\/strong> Veeva Systems<\/a> (NYSE:VEEV) today announced that more life sciences companies are adopting Veeva OpenData<\/a> to empower their field teams with faster, accurate customer data. Veeva OpenData provides access to approximately 16 million healthcare professionals (HCPs) and their healthcare organizations (HCOs) spanning 42 countries. Emerging biopharma and the largest pharmaceutical companies are using Veeva OpenData in various regions to increase field effectiveness and enhance customer engagement.<\/p>\n

Accurate, actionable data was critical for Nestl\u00e9 Health Science to improve efficiency of their sales teams. \u201cVeeva OpenData enables our sales reps to be more productive,\u201d said Rick Priem, global CRM manager for Nestl\u00e9 Health Science. \u201cWe have the insights we need to better understand what is happening in the field and drive improved customer interactions.\u201d<\/p>\n

Specialty pharmaceutical company, Indivior, previously had two data systems and worked from 17 different versions of the same data source across North America and Europe. This created an administrative burden on field reps managing customer information and left teams uncertain if they were working from the most current data such as physician addresses and specialty areas.<\/p>\n

Indivior moved to Veeva OpenData for one complete source of customer reference data to help field teams effectively and compliantly deliver new addiction treatment information to HCPs. Now HCP data is validated easier and faster, resulting in field teams that are confident they are leveraging the right customer information.<\/p>\n

\u201cBy switching to Veeva OpenData, we gained a single source of customer data that\u2019s accurate \u2013 a major advantage in today\u2019s varying compliance environment,\u201d said Dianne Goodburn, commercial director at Indivior.<\/p>\n

Veeva OpenData delivers fast, up-to-date customer data so field reps can focus on building trusted relationships with their customers. Data stewards validate and update data change requests in hours versus the industry average of 10 or more days.1<\/sup> Through integration of Veeva OpenData with Veeva CRM<\/a>, a sales representative can search and download data up to 60% faster and with 50% fewer clicks, allowing field reps to target the right physicians and opportunities in real-time.2<\/sup><\/p>\n

\u201cVeeva OpenData delivers quality customer data, right in CRM, to improve our sales execution,\u201d said Dipak Bhatti, managing director at Syner-Med<\/a>. \u201cOur sales reps can take a more targeted approach to field-based activities, helping improve the quality of our customer interactions.\u201d<\/p>\n

Veeva also makes it easier for companies to use and gain value from their customer data through an ecosystem of certified Veeva OpenData partners<\/a>. Expanded partnerships eliminate the need for multiple third-party agreements, shortening time and reducing costs of implementation.<\/p>\n

\u201cMany industry-leading companies are turning to Veeva OpenData as a complete source of customer data to improve sales execution, maintain compliance, and deliver accurate reporting and analytics,\u201d said Rebecca Silver, global vice president of Veeva OpenData. \u201cVeeva OpenData is becoming foundational for customers of all sizes in driving greater commercial success.\u201d<\/p>\n

1<\/sup> Veeva 2016 European Customer Data Survey <\/em>
\n2<\/sup> Veeva internal analysis <\/em><\/p>\n

Additional Information<\/strong>
\nFor more on Veeva OpenData, visit: veeva.com\/eu\/VeevaOpenData<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @Veeva_EU on Twitter: twitter.com\/veeva_eu <\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n

About Veeva Systems<\/strong>
\nVeeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n

###<\/p>\n

Contact:<\/strong>
\nSue Glanville \/ Cate Bonthuys
\nVeeva Systems Inc.
\nsue@catalystcomms.co.uk<\/a> \/ cate@catalystcomms.co.uk<\/a>
\n+44 (0) 7715 817589 \/ +44 (0) 7746 546773<\/p>\n","protected":false},"excerpt":{"rendered":"

Emerging biopharma and largest pharmaceutical companies improving field productivity and customer engagement.<\/p>\n","protected":false},"featured_media":20628,"parent":0,"template":"","class_list":["post-20480","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-commercial","resource-area-20-data","resource-product-20-customer-reference-data-opendata","resource-type-news-press-release"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t